| Cancer cohort | Non-cancer cohort |
---|---|---|
n  = 9,862 | n  = 15,483 | |
n (%) | n (%) | |
Sex | ||
  Female | 3,116 (31.6) | 7,521 (48.9) |
  Male | 6,746 (68.4) | 7,962 (51.4) |
Age at death | ||
  65–74 | 294 (3.0) | 254 (1.7) |
  75–84 | 4,075 (41.3) | 5,028 (32.5) |
  85–94 | 5,215 (52.9) | 9,232 (59.6) |
  95–104 | 277 (2.8) | 958 (6.2) |
  ≥105 | 1 (0.0) | 11 (0.1) |
Year of death | ||
  2005 | 1,204 (12.2) | 1,772 (11.4) |
  2006 | 2,236 (22.7) | 3,199 (20.7) |
  2007 | 2,351 (23.8) | 3,473 (22.4) |
  2008 | 2,133 (21.6) | 3,619 (23.4) |
  2009 | 1,938 (19.7) | 3,420 (22.1) |
Location of residence at death (remoteness area) | ||
  Major cities | 6,147 (62.3) | 9,530 (61.6) |
  Inner regional | 2,777 (28.2) | 4,400 (28.4) |
  Outer regional | 872 (8.8) | 1,410 (9.1) |
  Remote | 39 (0.4) | 81 (0.5) |
  Very remote | 5 (0.1) | 2 (0.0) |
  Missing | 22 (0.2) | 60 (0.4) |
Socioeconomic disadvantage index at death | ||
  (Most disadvantaged) 1–2 | 1,160 (11.8) | 1,862 (12.0) |
  3–4 | 2,831 (28.7) | 4,470 (28.9) |
  5–6 | 2,032 (20.6) | 3,085 (19.9) |
  7–8 | 1,418 (14.4) | 2,248 (14.5) |
  (Least disadvantaged) 9–10 | 2,019 (20.5) | 3,183 (20.6) |
  Missing | 402 (4.1) | 635 (4.1) |
Charlson comorbidity burden1 | ||
  0 | 3,105 (31.5) | 4,451 (28.8) |
  1–2 | 1,500 (15.2) | 2,068 (13.4) |
  ≥3 | 1,713 (17.4) | 1,578 (10.2) |
  No hospitalizations during calculation period (cannot calculate) | 3,544 (35.9) | 7,386 (47.7) |
RxRisk comorbidity burden2 | ||
  0 | 461 (4.7) | 846 (5.5) |
  1–2 | 1,298 (13.2) | 2,130 (13.8) |
  3–5 | 3,865 (39.2) | 6,104 (39.4) |
  ≥6 | 4,238 (43.0) | 6,403 (41.4) |